Whether this reflects formulation differences, batch variability, or individual sensitivity is difficult to determine without controlled comparison studies
After adjusting for potentially influential factors including age, sex, ethnicity, pre-existing conditions, other medication use, and body mass index, use of GLP-1 receptor agonists was associated with a 37% higher risk of alopecia than use of SGLT-2 inhibitors (6.91 v 5.04 per 1,000 person years) and a 68% higher risk than use of DPP-4 inhibitors (6.53 v 3.89 per 1,000 person years)
GLP-1 medications such as Wegovy, Ozempic, and Zepbound have become increasingly popular for treating obesity and Type 2 diabetes, but insurance coverage for these medications remains inconsistent and financially challenging for consumers who have resorted to getting their GLP1s through other avenues
Plus, hats, big glasses, and anything else I could do to be vigilant in protecting areas I did not want melanin to increase
Have insurance that covers GLP-1 weight loss medications: If your insurance plan covers Wegovy or Zepbound (which some plans do, particularly if you have documented comorbidities), your out-of-pocket costs through insurance may be lower than paying $233-$263/month for compounded versions
Consistent medical supervision is not just a preliminary step but an ongoing requirement for success